相关实验视频
Updated: May 10, 2026

15:48
ALS - Motor Neuron Disease: Mechanism and Development of New Therapies
Published on: July 29, 2007
9.6K
人类运动神经元中罕见的非编码基因变异的深度学习建模定义了CCDC146作为ALS的治疗标
Sai Zhang1,2,3,4, Tobias Moll5,4, Jasper Rubin-Sigler6,4
1Department of Epidemiology, University of Florida, Gainesville, FL, USA.
medRxiv : the preprint server for health sciences
|April 18, 2024
概括
研究人员开发了一种深度学习框架,以识别影响肌缩侧面硬化症 (ALS) 存活率的遗传变异. 他们发现了一种与CCDC146相关的新型变异,并且通过抗意义寡核酸治疗抑制它显示出治疗ALS的前景.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 计算生物学 计算生物学
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,其特征是运动神经元死亡.
- 了解影响ALS生存的遗传因素对于开发有效的治疗方法至关重要.
结论:
- 针对CCDC146的ASO向为ALS提供了潜在的广泛治疗策略.
- 开发的深度学习框架为研究复杂疾病中的非编码遗传学提供了强大的方法.
相关概念视频
siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

